Volume 11, Number 8—August 2005
Research
HIV-1 Genetic Diversity in Antenatal Cohort, Canada
Bertine S. Akouamba*†, Janique Viel*, Hugues Charest‡, Natacha Merindol*†, Johanne Samson*, Normand Lapointe*†, Bluma G. Brenner§, Richard Lalonde¶, P. Richard Harrigan#, Marc Boucher*†, and Hugo Soudeyns*†
Table
Viral and immune parameters in study participants*
| Overall |
Treatment naive |
||||||
|---|---|---|---|---|---|---|---|
| Median (IQR) viral load (log copies/mL)† | % viral load <2.7 (n)‡ | % viral load <1.7 (n)‡ | Median (IQR) CD4+ count (cells/μL)† | % receiving ARV therapy (n)‡ | Median (IQR) viral load (log copies/mL)† | Median (IQR) CD4+ cell count in treatment-naive patients (cells/μL)† | |
| HIV-1 B clade | 3.61 (1.71) | 28.8 (17) | 11.9 (7) | 360 (285) | 44.1 (26) | 3.95 (1.38) | 418 (278) |
| HIV-1 non-B clade | 3.52 (1.39) | 22.7 (10) | 2.27 (1) | 351 (220) | 20.5 (9) | 3.53 (0.94) | 327 (208) |
| p value | 0.927 | 0.508 | 0.316 | 0.476 | 0.0102§ | 0.143 | 0.107 |
*HIV-1 viral load and CD4+ cell counts were measured as described in Patients and Methods. Significance of differences between groups was tested by Kruskal-Wallis test or Fisher exact test. Analysis was carried out on the whole study group (N = 103) or restricted to those who did not receive treatment (n = 61). IQR, interquartile range; ARV, antiretroviral.
†Kruskal-Wallis test.
‡Fisher exact test.
§Statistically significant (p<0.05) by directional test.
